Resistance to EGFR-TKI Can Be Mediated Through Multiple Signaling Pathways Converging Upon Cap-Dependent Translation in EGFR-Wild Type NSCLC

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e31829ce963
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P009 to Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC With Wild-Type EGFR

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2017English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Cabozantinib Is More Effective Than Erlotinib in EGFR –Wild-Type NSCLC

Cancer Discovery
Oncology
2016English

Urea Cycle Sustains Cellular Energetics Upon EGFR Inhibition in EGFR Mutant NSCLC

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2019English

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy